CannTrust Holdings Inc. closed at $9.60 in the latest trading session, marking no change from the prior day. This change lagged the S&P 500's 0.12% gain on the day. Elsewhere, the Dow gained 0.23%, while the tech-heavy Nasdaq added 0.36%.
Prior to today's trading, shares of the company had gained 47.05% over the past month. This has outpaced the Medical sector's gain of 4.04% and the S&P 500's gain of 6.17% in that time.
Investors will be hoping for strength from CNTTF as it approaches its next earnings release. On that day, CNTTF is projected to report earnings of $0 per share, which would represent a year-over-year decline of 100%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $14.24 million, up 158.91% from the year-ago period.
Any recent changes to analyst estimates for CNTTF should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CNTTF is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note CNTTF's current valuation metrics, including its Forward P/E ratio of 48.01. This represents a premium compared to its industry's average Forward P/E of 16.67.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 62, putting it in the top 25% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Image: Bigstock
CannTrust Holdings Inc. (CNTTF) Flat As Market Gains: What You Should Know
CannTrust Holdings Inc. closed at $9.60 in the latest trading session, marking no change from the prior day. This change lagged the S&P 500's 0.12% gain on the day. Elsewhere, the Dow gained 0.23%, while the tech-heavy Nasdaq added 0.36%.
Prior to today's trading, shares of the company had gained 47.05% over the past month. This has outpaced the Medical sector's gain of 4.04% and the S&P 500's gain of 6.17% in that time.
Investors will be hoping for strength from CNTTF as it approaches its next earnings release. On that day, CNTTF is projected to report earnings of $0 per share, which would represent a year-over-year decline of 100%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $14.24 million, up 158.91% from the year-ago period.
Any recent changes to analyst estimates for CNTTF should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CNTTF is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note CNTTF's current valuation metrics, including its Forward P/E ratio of 48.01. This represents a premium compared to its industry's average Forward P/E of 16.67.
The Medical - Drugs industry is part of the Medical sector. This group has a Zacks Industry Rank of 62, putting it in the top 25% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.